166 related articles for article (PubMed ID: 25306106)
1. ¹⁸F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients.
Jiménez Londoño GA; García Vicente AM; Sánchez Pérez V; Jiménez Aragón F; León Martin A; Cano Cano JM; Domínguez Ferreras E; Gómez López OV; Espinosa Arranz J; Soriano Castrejón ÁM
Eur J Radiol; 2014 Dec; 83(12):2224-2230. PubMed ID: 25306106
[TBL] [Abstract][Full Text] [Related]
2. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
Ozkan E; Soydal C; Araz M; Aras G
Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
[TBL] [Abstract][Full Text] [Related]
4. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of F-18 FDG PET/CECT vs. CECT for detecting recurrence of periampullary carcinoma and its prognostic significance.
Santhosh S; Mittal BR; Kang M; Kapoor R; Gupta R; Rana S; Bhattacharya A; Bhasin D
Abdom Imaging; 2015 Jun; 40(5):1131-7. PubMed ID: 25655637
[TBL] [Abstract][Full Text] [Related]
6. The impact of 18F-FDG PET/CT in patients with liver metastases.
Chua SC; Groves AM; Kayani I; Menezes L; Gacinovic S; Du Y; Bomanji JB; Ell PJ
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1906-14. PubMed ID: 17713766
[TBL] [Abstract][Full Text] [Related]
7. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET.
García Vicente AM; Domínguez Ferreras E; Sánchez Pérez V; Poblete García VM; Villa Guzmán JC; Jiménez Aragón F; Pineda Pineda MD; Molino Trinidad C; Soriano Castrejón Á
Eur J Radiol; 2013 Jun; 82(6):e255-61. PubMed ID: 23414715
[TBL] [Abstract][Full Text] [Related]
8. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
10. Detection of recurrent colorectal cancer by 18F-FDG PET/CT comparison with contrast enhanced CT scan.
Chiewvit S; Jiranantanakorn T; Apisarnthanarak P; Kanchaanapiboon P; Hannanthawiwat C; Ubolnuch K; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2013 Jun; 96(6):703-8. PubMed ID: 23951828
[TBL] [Abstract][Full Text] [Related]
11. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
12. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
13. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
[TBL] [Abstract][Full Text] [Related]
15. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
16. The value of (18) F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction.
Müller J; Hüllner M; Strobel K; Huber GF; Burger IA; Haerle SK
Laryngoscope; 2015 Aug; 125(8):1861-8. PubMed ID: 25892275
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic value of ¹⁸F-fluorodexyglucose positron emission tomography combined with contrast enhanced computed tomography in colorectal cancer liver metastasis].
Zhang Z; Lyu Q; Chen F; Liao S; Zhang J; Hu R; Hu P
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Mar; 18(3):238-42. PubMed ID: 25809326
[TBL] [Abstract][Full Text] [Related]
18. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G
Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
